NeoGenomics, Inc. (NEO)

NeoGenomics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-84.23	-87.97	-144.25	-8.35	4.17	8.01
Depreciation & Amortization	82.33	81.82	79.21	62.07	41.89	35.91
Share-Based Compensation	27.65	24.63	24.67	22.46	10.21	10
Other Operating Activities	-40.92	-20.44	-25.62	-102.9	-54.81	-30.54
Operating Cash Flow	-15.18	-1.95	-65.99	-26.72	1.46	23.37
Operating Cash Flow Growth	-	-	-	-	-93.75%	-47.82%
Capital Expenditures	-24.41	-28.75	-30.89	-64.14	-29.1	-20.03
Acquisitions	0	0	0	-434.4	-62.6	0.4
Change in Investments	91.9	105.46	19.31	-133.82	-67.75	0
Other Investing Activities	-	-	12.1	-	-	-
Investing Cash Flow	67.49	76.71	0.52	-632.37	-159.44	-19.63
Share Issuance / Repurchase	4.03	4.62	12.59	423.21	147.6	171.98
Debt Issued / Paid	-0.04	-0.07	-0.76	331.36	91.31	-12.51
Other Financing Activities	-	-	-	-29.29	-3.32	-
Financing Cash Flow	3.99	4.55	11.83	725.29	235.6	159.47
Net Cash Flow	56.31	79.31	-53.65	66.2	77.62	163.21
Free Cash Flow	-39.59	-30.71	-96.88	-90.87	-27.64	3.34
Free Cash Flow Growth	-	-	-	-	-	-89.04%
Free Cash Flow Margin	-6.48%	-5.19%	-19.01%	-18.76%	-6.22%	0.82%
Free Cash Flow Per Share	-0.31	-0.24	-0.78	-0.76	-0.26	0.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).